PLX (Protalix) EV/EBITDA Multiple

Corporate emblem and logo of Protalix BioTherapeutics, Inc (PLX)

Protalix BioTherapeutics (PLX) is striving for the global promotion of Elfabrio and the expansion of B2B connections through the ProCellEx system. The market capitalization trend reflects a value of 7.01. Dror Bashan's team is betting on a scientific foundation and systemic planning in drug development. The stability of global shipments is ensured by engaging external manufacturing behemoths, which eliminates capacity shortages during enzyme production.

Protalix BioTherapeutics, Inc - PLX Enterprise Value to Operating Income Before Depreciation (period 11/23/2025 - 11/10/2026)

Financial and market metric breakdowns for protalix.com (PLX)

- stock price and consensus target price:
Stock Quotes Protalix|PLX - Forecast Levels Chart
- business market valuation indicators:
Market Capitalization Protalix BioTherapeutics, Inc|PLX - Total Enterprise Value
- issuer book value statistics:
Book Value per Share Protalix BioTherapeutics|PLX - Accounting Capitalization|Market Cap to Net Assets Ratio protalix.com|PLX - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Protalix BioTherapeutics|PLX - Long-Term Liabilities to Equity|Short-Term Debt to Capital Protalix BioTherapeutics, Inc.|PLX - Aggregate Debt Obligations|Debts to Book Capitalization Protalix BioTherapeutics, Inc|PLX - Company Long-Term Debts|Company Short-Term Debt Protalix BioTherapeutics|Quick Liquidity protalix.com
- financial results and valuation multiples details:
PLX - Net Income|Projected Future Earnings Protalix BioTherapeutics|PLX - P/E Multiple|Future Price to Earnings Protalix BioTherapeutics|PLX - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix BioTherapeutics, Inc|PLX - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Protalix BioTherapeutics|PLX - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months protalix.com|PLX - Net earnings per one share growth for the current year|Earnings growth forecast for next year Protalix BioTherapeutics
Summary company analysis:Protalix PLX
Original product of protalix.com

This ratio determines the market value of the business, accounting for net debt relative to operating profit before depreciation and amortization. It allows an investor to assess the real value of assets by excluding the impact of taxes and financing structures. By analyzing the historical EV/EBITDA trend of the company, one can identify the asset's fundamental bottom during periods of volatility. For Protalix BioTherapeutics (PLX), this indicator is critical, as it helps balance the risks of single-drug dependency with the stability of a global partnership.

Competitors of Protalix BioTherapeutics

Vertex Pharmaceuticals Inc. - Enterprise Value to EBITDA Ratio|ALNY (Alnylam Corp) - Company Value to Operating Income Before Depreciation Ratio|Insmed Incorporated - EV/EBITDA Multiple|Company Value to EBITDA unither.com|BMRN: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation BBIO|Enterprise Value to EBITDA Ratio BGM|COGT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xeris Biopharma (XERS)|KROS: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ARCT (Arcturus Therapeutics Holdings Inc.)|Business Value to Operating Income Before Depreciation ETON|Kamada Corp - EV/EBITDA Multiple|FULC - EV/EBITDA Multiple|abeonatherapeutics.com (ABEO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Mereo BioPharma Group plc - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pliant Therapeutics Inc|Enterprise Value to EBITDA Ratio Applied Therapeutics Inc. (APLT)|EV/EBITDA Multiple RNTX|EV/EBITDA Multiple gelteq.com (GELS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aytu BioPharma AYTU|CMMB (Chemomab Therapeutics Ltd) - Company Value to Operating Income Before Depreciation Ratio|SRXH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation PLRZ (Polyrizon Ltd)|zentaris.com (AEZS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Cyclo Therapeutics, Inc (CYTH)|Enterprise Value to EBITDA Ratio INZY|RPHM (reneopharma.com) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CSCI